Of significance, increased levels of PAF agonists or PAFR activity have been detected in perfusates and tumor samples collected post-chemotherapy and post-radiation therapy compared to pre-chemotherapy and pre-radiation therapy in melanoma and non-melanoma patients [9, 14]. This evidence concerns the gene PCLAF and melanoma.